Telomir Pharmaceuticals, Inc. (NasdaqCM: TELO)
Health Care · Pharmaceuticals · US
$1.18
+8.26% today · -26.8% 1Y
Telomir Pharmaceuticals, Inc. (NasdaqCM: TELO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $74.96M and employs 2 people.
Over the last twelve months the share price has lost 26.8%, trading between 0.89 and 2.09.
Tweenvest scores Telomir Pharmaceuticals, Inc. across four factors: quality 26/100. Its strongest factor is quality.
TELO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $74.96M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.29
- Dividend yield
- —
- Beta (5Y)
- -0.24
- 52-week high
- $2.09
- 52-week low
- $0.89
- Avg volume (3M)
- —
- Shares outstanding
- 68.77M
- Employees
- 2
- Next earnings
- —
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
- ISIN
- US87975F1049
- Founded
- 2021
- Listed since
- Feb 9, 2024
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.